Gonzalez, Angel
Belmonte, Irene
Nuñez, Alexa
Farago, Georgina
Barrecheguren, Miriam
Pons, Mònica
Orriols, Gerard
Gabriel-Medina, Pablo
Rodríguez-Frías, Francisco
Miravitlles, Marc
Esquinas, Cristina
Funding for this research was provided by:
Grifols
FUCAP
Article History
Received: 29 March 2022
Accepted: 1 December 2022
First Online: 10 December 2022
Declarations
:
: Ethics approval and consent to participate the study was carried out according to the principles of the Declaration of Helsinki and the prevailing norms for performing investigation in humans. Data confidentiality was ensured according to the Law of Data Protection 2016/679. The study was approved by the Ethical Committee and Clinical Investigation of the Vall d’Hebron University Hospital (Barcelona, Spain) number PR (AG) 156/2016, and all the participants provided written informed consent.
: Not applicable.
: Cristina Esquinas has received speaker fees from CSL Behring. Marc Miravitlles has received speaker or consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Kamada, GlaxoSmithKline, Grifols, Menarini, Mereo Biopharma, Novartis, pH Pharma, Palobiofarma SL, TEVA, Spin Therapeutics, Speciality Therapeutics, Jansen, and Zambon, and research grants from Grifols. Miriam Barrecheguren has received speaker fees from Grifols, Menarini, CSL Behring, GSK and consulting fees from GSK, Novartis, Boehringer Ingelheim and Gebro Pharma. The remaining authors report no conficts of interest.